Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take aim at Hard-to-Treat childhood leukemia

NCT ID NCT07695012

Recruiting now Disease control Sponsor: Dr. Zaineb Akram Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial investigates a personalized cell therapy called CAR-T for children and young adults (ages 5–50) with B-cell acute lymphoblastic leukemia that has relapsed or not responded to standard treatment. The therapy involves collecting a patient's own immune cells, engineering them to recognize and attack cancer cells, and infusing them back. The study aims to assess whether this approach is safe and feasible to manufacture locally, with a focus on monitoring side effects like cytokine release syndrome.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CAR-T cell therapy (anti-CD19 chimeric antigen receptor T-cells)
What this could lead to
If successful, this approach could offer a new treatment option for patients whose leukemia has returned or not responded to standard therapies, potentially improving remission rates.
What could go wrong
This is an early-phase, small study (10 participants) focused on safety, so it may not show strong effectiveness. Risks include severe immune reactions like cytokine release syndrome (CRS) and neurological side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National University of Medical Sciences, Clinical Trial Unit

    RECRUITING

    Rawalpindi, 46000, Pakistan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.